Nonetheless, we found that the clinical performance of this screening algorithm remained satisfactory in the pooled validation cohort with reasonable sensitivity and high NPV of over 90%, indicating that this algorithm should be also applicable to individuals who are relatively insulin resistant either due to PCOS or more severe obesity. This evidence concerns the gene INS and obesity disorder.